Osteoprotegerin

Details Osteoprotegerin Osteoprotegerin

2000-11-22

2009-12-15

Allen, Marianne P (Department: 1647)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S387300, C530S387900, C530S388100, C530S391100, C435S007100

Reexamination Certificate

active

07632922

ABSTRACT:
The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4710473 (1987-12-01), Morris
patent: 5447851 (1995-09-01), Beutler et al.
patent: 0 401 384 (1990-12-01), None
patent: 0816380 (1998-07-01), None
patent: 7-207508 (1995-02-01), None
patent: 7-054977 (1995-07-01), None
patent: WO 90/14363 (1990-11-01), None
patent: WO 94/21670 (1994-09-01), None
patent: WO95/11308 (1995-04-01), None
patent: 9605309 (1996-02-01), None
patent: WO96/26217 (1996-08-01), None
patent: WO 96/28546 (1996-09-01), None
patent: WO96/28546 (1996-09-01), None
patent: WO98/12344 (1998-03-01), None
Well, J. Additivity of Mutational Effects in Proteins. Biochemistry 29:8509-8517 (1990).
Daniel et al. Mapping of Linear Antigenic Sites on the S Glycoprotein of a Neurotropic Murine Coronavirus with Synthetic Peptides: Virology 202 pp. 540-549 (1994).
Alexander et al. Altering the antigenicity of proteins. Proc. Natl. Acad. Sci. USA vol. 89, pp. 3352-3356 (Apr. 1992).
Wells, Additivity of Mutational Effects in Proteins: Biochemistry vol. 29/37, pp. 8509-8517 (1990).
Ngo et al. Computational complexity, protein structure prediction, and the levinthal paradox. The protein folding problem and tertiary structure prediction, pp. 433-440 and 492-495. Merz and Le Grand, Editors, (Birkhauser Boston 1994).
Abbas et al. Cellular and Molecular Immunology, pp. 47-48. Second Edition. W.B. Saunders Company, Philadelphia (1994).
Banner et al. Cell 73, 431-445 (1993).
Beutler and van Huffel Science 264, 667-663 (1994).
Beutler et al. Ann. Rev., Biochem. 57, 505-518 (1988).
Brinster et al., Proc. Natl. Acad. Sci. USA 82, 4338 (1985).
Capon et al. Nature 337, 525-531 (1989).
Chen et al., Chemistry 270, 2874-2878 (1995).
Chomczynski and Sacchi Anal. Biochem. 162, 156-159, (1987).
Chou and Fasman Adv. Enz. 47, 45-147 (1948).
DeClerck et. atl. J. Biol. Chem. 266, 3893 (1991).
Eisenberg et al. Proc. Natl. Acad. Sci. USA 81, 140-144 (1984).
Lewis et al., Proc. Natl. Acad. Sci. USA 88, 2830-2834 (1991).
Ellison et al. (Nuc. Acids Res. 10, 4071-4079 (1982).
Fisher et al. Cell 81, 935-946 (1995).
Gennaro A.R.,Remington's Pharmaceutical Sciences, 18th ed. Mack, Easton, PA (1980).
Goeddel et al. Cold Spring Harbor Symp. Quart. Biol. 51, 597-609 (1986).
Goeddel, D.V.,Methods of Enzymologyv. 185, ed. Academic Press (1990).
Goldman et al. Ann. Rev. Biophys. Biophys. Chem. 15, 321-353 (1986).
Gribskov et al. (Proc. Natl. Acad. Sci. USA 83, 4355-4359 (1987).
Harlow and Lane,Antibodies: A Laboratory ManualCold Spring Harbor Laboratory Press, Cold Spring Harbor N.Y. (1988).
Heldin, Cell 80, 213-223 (1995).
Kohno et al. PNAS USA 87, 8331-8335 (1990).
Kraulis, J. Appl. Cryst. 24, 946-950, 1991).
Kyte and Doolittle (J. Mol. Biol. 157, 105-132 (1982).
Loetscher et al. Cancer Cells 3(6), 221-226 (1991).
Luethy et al. (Protein Science 3, 139-146 (1994).
Malik et al., Exp. Hematol. 20: 1028-1035 (1992).
Matsudaira et al. J. Biol. Chem. 262, 10-35 (1987).
McDonald et al. Meth. Enzymol. 152, 219 (1987).
Nagata et al. Science 267, 1449-1456 (1995).
Ogden et al. Meth. Enzymol 152, 61 (1987).
Pearson et al. Meth. Enzymol. 183, (1990).
Sambrook et al.Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989).
Simonet et al. J. Clin, Invest. 94, 1310-1319 (1994).
Smith, et al. Cell 76, 953-962 (1994).
Suda et al. Cell 75, 1169-1178 (1993).
Wigler et al. Cell 11, 233 (1977).
Presentation at Joint Annual Conference Japanase Biochemical Society & Japanese Microbiological Society, Aug. 26, 1996-Aug. 30, 1996 Abstracts 1-P-0538 and 1-P-0544.
Abbas et al., Cellular and Molecular Immunology, pp. 47-48, Second Edition. W.B. Saunders Company, Philadelphia (1994).
Alexander et al., “Altering the Antigenicity of Proteins”,:Pro. Natl. Acad. Sci., 89, 3352-3356 (1992).
Garcia et al., “Transgenic Mice Expressing High Levels of Soluble TNF-R1 Fusion Protein are Protected from Lethal Septic Shock and Cerebral Malaria, and are Highly Sensitive to Listeria Monocytogenes and Leishmania Major Infections”,Eur. J. Immunol, 2401-2407 (1995).
Himmler et al., “Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein”,DNA and Cell Biology, 9(10), 705-715 (1990).
Ngo et al., Computational Complexity Protein Structure Prediction, and the Levinthal Paradox, The Protein Folding Problem and Tertiary Structure Prediction, pp. 433-440 and 492-495. Merz and Le Grand, Editors, (Birkhauser Boston 1994).
Wells, James A., “Additivity of Mutational Effects in Proteins”,Biochemistry, 29(37) 8509-8517 (1990).
Adams et al., “Complementary DNA sequencing: expressed sequence tags and human genome project”, Science, 252: 1651-1656 (1991).
Anderson W. F., “Prospects for Human Gene Therapy”, Science, 226: 401-409 (1984).
Baylink et al., “The diagnosis and treatment of osteoporosis: future prospects”, Mol. Med. Today, pp. 133-140 (1999).
Bork et al., “Go hunting in sequence databases but watch out for the traps”, Trends in Genetics, 12: 425-427 (1996).
Bork, P., “Powers and pitfalls in sequence analysis: The 70% hurdle”, Genome Research, 10: 398-400 (2000).
Brenner, S., “Errors in genome annotation”, Trends in Genetics, 15: 132-133 (1999).
Buckel, “Recombinant proteins for therapy”, Trends in Pharmacol. Sciences, 17(12):450-456 (1996).
Crystal, R. G., “Transfer of Genes to Humans: Early Lessons and Obstacles to Success”, Science, 270: 404-410 (1995).
Doerks et al., “Protein annotation: detective work for function prediction”, Trends in Genetics, 14: 248-250 (1998).
Deonarain, M. P., “Ligand-targeted receptor-mediated vectors for gene delivery”, Expert Opin. Ther. Patemts, 8(1): 53-69 (1998).
Eck et al., Gene-based therapy, Chapter 5, pp. 77-101, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill (1996).
Anderson, W. French,“The current status of clinical gene therapy”, Human Gene Therapy, 13: 1261-1262 (2002).
Miller, N. et al., “Targeted vectors for gene therapy”, FASEB J., 9: 190-199 (1995).
Orkin et al., www.nih.gov
ews/panelrep.html, pp. 1-36 (Dec. 1995).
Rodan et al., “Therapeutic approaches to bone disease”, Science, 289: 1508-1514 (2000).
Robbins et al., “Viral vectors for gene therapy”, Pharmacol Ther, 80(1): 35-47 (1998).
Simonet et al., “Osteoprotegrin: A Novel Secreted Protein Involved in the Regulation of Bone Density”, Cell, 89:309-319 (1997).
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era”, Trends in Biotech, 18(1): 34-39 (2000).
Smith et al., The challenges of genome sequence annotation or “The devil is in the details”, Nature Biotechnology, 15: 1222-1223 (1997).

Affiliated with

Also associated with

Rating

Osteoprotegerin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Osteoprotegerin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Osteoprotegerin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4131625